Vascular Control of NASH Progression
This project aims to characterize the gut-liver vasculature in NASH progression using spatial sorting and imaging to identify therapeutic targets and prognostic markers for HCC.
Projectdetails
Introduction
Non-alcoholic steato-hepatitis (NASH) is a major risk factor for hepatocellular carcinoma (HCC), the 6th most common cause of cancer-related death worldwide. The transition among different NASH stages to HCC stems from the complex interaction of multiple factors, including gut-liver axis modifications and a progressive dis-architecture of the liver parenchyma.
Endothelial Cells and NASH Progression
The central role of endothelial cells in regulating the metabolic crosstalk along the gut-liver axis and in shaping the spatial organization of the liver parenchyma suggests a potential vascular control of NASH progression. However, the possibility to precisely define the endothelial contribution is restrained by the limited ability to correlate gene expression profiling and functional readout, such as protein phosphorylation, with the complex morphological modifications occurring during NASH.
Methodology
To overcome these limitations, we combined innovative “spatial sorting” strategies with transcriptomics and quantitative phosphoproteomics, providing the first draft of the anatomical organization of proteins signaling in the liver vasculature. Moreover, we unambiguously identified tyrosine phosphorylation – the main target of the anti-angiogenic therapy (ATT) – as one of the most spatially regulated signaling events.
Research Aims
Building on this expertise, we will combine spatial sorting strategies in gut and liver with mouse models of NASH progression and advanced imaging modalities to pursue the following aims:
- Provide a spatiotemporal characterization of the gut and liver vasculature undergoing NASH development.
- Dissect the vascular determinants of NASH progression.
- Identify the molecular mechanisms underlying the synergistic effect between AAT and immune checkpoint inhibition.
Conclusion
Together, our results will lay the foundation for understanding the molecular basis of a synergistic AAT and immune therapy in HCC, and help to identify novel prognostic markers as well as potential therapeutic targets.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.741.250 |
Totale projectbegroting | € 1.741.250 |
Tijdlijn
Startdatum | 1-10-2024 |
Einddatum | 30-9-2029 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- UNIVERSITA VITA-SALUTE SAN RAFFAELEpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Validation of a new drug target in non-alcoholic steatohepatitisThis project aims to explore oxidative stress's role in non-alcoholic steatohepatitis (NASH) and develop new treatments by targeting MAP kinases p38 and JNK. | ERC Proof of... | € 150.000 | 2023 | Details |
A novel NASH model for target and drug candidate identificationThe SPHERO-NASH project aims to develop a 3D liver model for studying NASH mechanisms and drug discovery, facilitating commercialization of novel therapeutic targets and compounds. | ERC Proof of... | € 150.000 | 2023 | Details |
Understanding Metabolic Activation of Dendritic Cells in Non-Alcoholic Fatty Liver DiseaseThis project aims to investigate the role of conventional dendritic cells in non-alcoholic steatohepatitis by exploring their immuno-metabolic functions and interactions with liver metabolism. | ERC Starting... | € 2.406.250 | 2022 | Details |
Scalable target identification for metabolic liver diseaseThe 3DMASH project aims to identify novel pharmacological targets for metabolic dysfunction-associated steatohepatitis by mapping tissue interactions using patient-derived organotypic cultures. | ERC Consolid... | € 1.950.000 | 2025 | Details |
Generating mRNA-HNF4a-Lipid nanoparticles for curing pancreatic cancer-associated cachexia (CAC) in identified patients at riskThis project aims to develop and test liver-specific mRNA therapies targeting HNF4a to prevent or alleviate cancer-associated cachexia in pancreatic cancer patients identified by a novel liver score. | ERC Proof of... | € 150.000 | 2023 | Details |
Validation of a new drug target in non-alcoholic steatohepatitis
This project aims to explore oxidative stress's role in non-alcoholic steatohepatitis (NASH) and develop new treatments by targeting MAP kinases p38 and JNK.
A novel NASH model for target and drug candidate identification
The SPHERO-NASH project aims to develop a 3D liver model for studying NASH mechanisms and drug discovery, facilitating commercialization of novel therapeutic targets and compounds.
Understanding Metabolic Activation of Dendritic Cells in Non-Alcoholic Fatty Liver Disease
This project aims to investigate the role of conventional dendritic cells in non-alcoholic steatohepatitis by exploring their immuno-metabolic functions and interactions with liver metabolism.
Scalable target identification for metabolic liver disease
The 3DMASH project aims to identify novel pharmacological targets for metabolic dysfunction-associated steatohepatitis by mapping tissue interactions using patient-derived organotypic cultures.
Generating mRNA-HNF4a-Lipid nanoparticles for curing pancreatic cancer-associated cachexia (CAC) in identified patients at risk
This project aims to develop and test liver-specific mRNA therapies targeting HNF4a to prevent or alleviate cancer-associated cachexia in pancreatic cancer patients identified by a novel liver score.